ArticleBMC gastroenterology2025
Dynamic variations in peripheral blood indices and their association with efficacy and adverse reactions of pd- 1 inhibitor combined chemotherapy in patients with advanced gastric cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A composite biomarker based on early dynamic changes in lactate dehydrogenase and PD-L1 expression enhances outcome prediction for immunochemotherapy in HER2-negative advanced gastric cancer.Frontiers in immunology · 2026Article
- Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring.Frontiers in immunology · 2026Review
- Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Observational
- Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature.Frontiers in oncology · 2025Article
- Circulating PD-1Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGastric cancer (GC) continues to pose a significant global health challenge, particularly in advanced stages where treatment options are severely constrained. Immunotherapy represents a groundbreaking advancement in cancer treatment, exhibiting promising therapeutic effects in patients diagnosed with gastric cancer. However, the efficacy of immunotherapy is not universally applicable to all individuals. Revealing precise biomarkers for tumor immunotherapy as targets or indicators for detection and evaluation can facilitate the resolution of this predicament. This study aims to identify serum tumor markers and blood cell ratios as predictive biomarkers to aid in the selection of gastric cancer patients who may benefit from PD-1 inhibitors therapy.
methodsA retrospective analysis was conducted on the medical records and hematological data of 98 patients with HER2-negative and microsatellite-stable (MSS) metastatic gastric cancer who received first-line treatment with PD-1 inhibitors in combination with chemotherapy at our institution. We investigated peripheral blood parameters, including Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), C-Reactive Protein-to-Albumin Ratio (CAR), AFP, Carcinoembryonic Antigen (CEA), and Sugar antigens 199 (CA199). Logistic regression and Cox regression analyses were employed to assess the correlation of these parameters with treatment response and survival duration. The relationship between these indicators and overall survival was assessed by employing Kaplan-Meier survival curves, in conjunction with an analysis of Overall Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), Overall Survival (OS), and safety profiles..
resultsHigher pre-treatment levels of NLR, CAR, AFP, and CA199, along with subsequent reductions in NLR, CAR, and CA199 at 12 weeks post-treatment, were significantly associated with extended PFS and OS. Multivariate Cox analysis suggested that pre-treatment levels of AFP, as well as the reduction in NLR and CA199 at 12 weeks post-treatment, were strongly correlated with PFS and OS in patients with gastric cancer undergoing immunotherapy. Additionally, the reduction in NLR, CAR, and CA199 observed at 12 weeks after treatment showed a significant positive correlation with improved DCR and ORR. Multivariate logistic regression analysis indicated that the decline in NLR and CA199 levels at 12 weeks post-treatment might be associated with DCR, while pre-treatment CAR levels and the decrease in CAR after 12 weeks could potentially predict ORR in immunotherapy for gastric cancer. Notably, patients with normal AFP levels exhibited significantly prolonged median progression-free survival (mPFS) of 6.8 months and median overall survival (mOS) of 13.2 months compared to those with elevated AFP levels (mPFS: 5.2 months; mOS: 9.4 months), and this difference was statistically significant (P < 0.05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.